216 related articles for article (PubMed ID: 37306188)
21. Development and validation of nomograms integrating immune-related genomic signatures with clinicopathologic features to improve prognosis and predictive value of triple-negative breast cancer: A gene expression-based retrospective study.
Wang K; Li HL; Xiong YF; Shi Y; Li ZY; Li J; Zhang X; Li HY
Cancer Med; 2019 Feb; 8(2):686-700. PubMed ID: 30677255
[TBL] [Abstract][Full Text] [Related]
22. Identification of necroptosis-related subtypes and prognosis model in triple negative breast cancer.
Pu S; Zhou Y; Xie P; Gao X; Liu Y; Ren Y; He J; Hao N
Front Immunol; 2022; 13():964118. PubMed ID: 36059470
[TBL] [Abstract][Full Text] [Related]
23. Characterization of Exosome-Related Gene Risk Model to Evaluate the Tumor Immune Microenvironment and Predict Prognosis in Triple-Negative Breast Cancer.
Qiu P; Guo Q; Yao Q; Chen J; Lin J
Front Immunol; 2021; 12():736030. PubMed ID: 34659224
[TBL] [Abstract][Full Text] [Related]
24. Identification of Hypoxia-Related Subtypes, Establishment of Prognostic Models, and Characteristics of Tumor Microenvironment Infiltration in Colon Cancer.
Wang C; Tang Y; Ma H; Wei S; Hu X; Zhao L; Wang G
Front Genet; 2022; 13():919389. PubMed ID: 35783281
[No Abstract] [Full Text] [Related]
25. Prognostic value and immune landscapes of TERT promoter methylation in triple negative breast cancer.
Lin F; Huang J; Zhu W; Jiang T; Guo J; Xia W; Chen M; Guo L; Deng W; Lin H
Front Immunol; 2023; 14():1218987. PubMed ID: 37575241
[TBL] [Abstract][Full Text] [Related]
26. Integrated multi-cohorts for characterizing the immunogenomic landscape and predicting drug response in triple-negative breast cancer.
Su D; Chi M; Wang S; Di S; Zhang H; Lu Q; Yu Y; Xiong Y; Wei H; Lv Y; Zuo Y; Yang L
Brief Funct Genomics; 2022 May; 21(3):188-201. PubMed ID: 35348574
[TBL] [Abstract][Full Text] [Related]
27. Identification of DDIT4 as a potential prognostic marker associated with chemotherapeutic and immunotherapeutic response in triple-negative breast cancer.
Chen X; Li Z; Liang M; Zhang Z; Zhu D; Lin B; Zhou R; Lu Y
World J Surg Oncol; 2023 Jun; 21(1):194. PubMed ID: 37391802
[TBL] [Abstract][Full Text] [Related]
28. Molecular Characterization and Establishment of a Prognostic Model Based on Primary Immunodeficiency Features in Association with RNA Modifications in Triple-Negative Breast Cancer.
Xia H; Xu X; Guo Y; Deng X; Wang Y; Fu S
Genes (Basel); 2023 Dec; 14(12):. PubMed ID: 38136994
[TBL] [Abstract][Full Text] [Related]
29. Single-cell and bulk RNA sequencing analysis of B cell marker genes in TNBC TME landscape and immunotherapy.
Zhao F; Zhao C; Xu T; Lan Y; Lin H; Wu X; Li X
Front Immunol; 2023; 14():1245514. PubMed ID: 38111587
[TBL] [Abstract][Full Text] [Related]
30. Nomogram Personalizes and Visualizes the Overall Survival of Patients with Triple-Negative Breast Cancer Based on the Immune Genome.
Wang P; Fu Y; Chen Y; Li Q; Hong Y; Liu T; Ding Z
Biomed Res Int; 2020; 2020():4029062. PubMed ID: 33299869
[TBL] [Abstract][Full Text] [Related]
31. An iron metabolism and immune related gene signature for the prediction of clinical outcome and molecular characteristics of triple-negative breast cancer.
Li XF; Fu WF; Zhang J; Song CG
BMC Cancer; 2022 Jun; 22(1):619. PubMed ID: 35668369
[TBL] [Abstract][Full Text] [Related]
32. Establishment and validation of an aging-related risk signature associated with prognosis and tumor immune microenvironment in breast cancer.
Wang Z; Liu H; Gong Y; Cheng Y
Eur J Med Res; 2022 Dec; 27(1):317. PubMed ID: 36581948
[TBL] [Abstract][Full Text] [Related]
33. A novel tumor-associated neutrophil gene signature for predicting prognosis, tumor immune microenvironment, and therapeutic response in breast cancer.
Zhang J; Wang X; Zhang Z; Ma F; Wang F
Sci Rep; 2024 Mar; 14(1):5339. PubMed ID: 38438469
[TBL] [Abstract][Full Text] [Related]
34. Immune checkpoints expression patterns in early-stage triple-negative breast cancer predict prognosis and remodel the tumor immune microenvironment.
Zhang J; Jin H; Pan S; Han C; Sun Q; Han X
Front Immunol; 2023; 14():1073550. PubMed ID: 36814908
[TBL] [Abstract][Full Text] [Related]
35. Immune landscape and risk prediction based on pyroptosis-related molecular subtypes in triple-negative breast cancer.
Luo L; Wei Q; Xu C; Dong M; Zhao W
Front Immunol; 2022; 13():933703. PubMed ID: 36189269
[TBL] [Abstract][Full Text] [Related]
36. Single-cell atlas reveals a distinct immune profile fostered by T cell-B cell crosstalk in triple negative breast cancer.
Ding S; Qiao N; Zhu Q; Tong Y; Wang S; Chen X; Tian Q; Xiao Y; Shen K
Cancer Commun (Lond); 2023 Jun; 43(6):661-684. PubMed ID: 37158690
[TBL] [Abstract][Full Text] [Related]
37. An EMT-Related Gene Signature to Predict the Prognosis of Triple-Negative Breast Cancer.
Zhang B; Zhao R; Wang Q; Zhang YJ; Yang L; Yuan ZJ; Yang J; Wang QJ; Yao L
Adv Ther; 2023 Oct; 40(10):4339-4357. PubMed ID: 37462865
[TBL] [Abstract][Full Text] [Related]
38. A Machine Learning Model to Predict the Triple Negative Breast Cancer Immune Subtype.
Chen Z; Wang M; De Wilde RL; Feng R; Su M; Torres-de la Roche LA; Shi W
Front Immunol; 2021; 12():749459. PubMed ID: 34603338
[TBL] [Abstract][Full Text] [Related]
39. An exosome-based specific transcriptomic signature for profiling regulation patterns and modifying tumor immune microenvironment infiltration in triple-negative breast cancer.
Wang H; Wang R; Luo L; Hong J; Chen X; Shen K; Wang Y; Huang R; Wang Z
Front Immunol; 2023; 14():1295558. PubMed ID: 38124743
[TBL] [Abstract][Full Text] [Related]
40. Identification of immune-related signature for the prognosis and benefit of immunotherapy in triple-negative breast cancer.
Sun X; Zhang T
Front Genet; 2022; 13():1067254. PubMed ID: 36452159
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]